Gilboa Therapeutics

Company Overview

Snapshot

Founded in October 2019 by Yaron Carmi, Gilboa Therapeutics operates with 1–10 employees. The company has secured funding across one round from one investor, NFX Capital. Gilboa Therapeutics ceased operations in July 2025.

Business overview

Gilboa Therapeutics is a preclinical-stage cancer immunotherapy company developing next-generation cell therapy for cancer treatment. Its core product, SolidT, is designed to harness the patient's immune system to treat a range of cancers by delivering a specific and potent attack that has demonstrated complete eradication of tumors in animal models while leaving healthy tissue unharmed. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare industry.

Company Intelligence Q&A

What is Gilboa Therapeutics' primary focus?

Gilboa Therapeutics is focused on developing next-generation cell therapy for the treatment of cancer, aiming to improve outcomes and save lives.

When was Gilboa Therapeutics founded?

Gilboa Therapeutics was founded in October 2019.

Who are the founders of Gilboa Therapeutics?

Gilboa Therapeutics was co-founded by Yaron Carmi.

What is SolidT?

SolidT is Gilboa Therapeutics' next-generation cell therapy designed to harness a patient's immune system to treat a wide range of cancers, demonstrating tumor eradication in animal models while sparing healthy tissue.

What is the current operational status of Gilboa Therapeutics?

Gilboa Therapeutics ceased to operate in July 2025.